32. Meacham, C.E., Ho, E.E., Dubrovsky, E., Gertler, F.B. & Hemann, M.T. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. *Nat Genet* **41**, 1133-7 (2009).
33. Luo, B. et al. Highly parallel identification of essential genes in cancer cells. *Proc Natl Acad Sci U S A* **105**, 20380-5 (2008).
34. Konstantinopoulos, P.A. & Papavassiliou, A.G. Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy. *Trends Pharmacol Sci* **28**, 6-13 (2007).
35. Bellosta, S., Paoletti, R. & Corsini, A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. *Circulation* **109**, III50-7 (2004).
36. Langdon, W.Y. FLT3 signaling and the development of inhibitors that target FLT3 kinase activity. *Crit Rev Oncog* **17**, 199-209 (2012).
37. Weiss, R.B. The anthracyclines: will we ever find a better doxorubicin? *Semin Oncol* **19**, 670-86 (1992).
38. Gupta, P.B. et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. *Cell* **138**, 645-59 (2009).
39. Yeh, J.R. et al. Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. *Nat Chem Biol* **5**, 236-43 (2009).
40. Sachlos, E. et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. *Cell* **149**, 1284-97 (2012).
41. Dimitroulakos, J. et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. *Blood* **93**, 1308-18 (1999).
42. Li, H.Y., Appelbaum, F.R., Willman, C.L., Zager, R.A. & Banker, D.E. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. *Blood* **101**, 3628-34 (2003).
43. Osmak, M. Statins and cancer: Current and future prospects. *Cancer Lett* **324**, 1-12 (2012).
44. Kornblau, S.M. et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. *Blood* **109**, 2999-3006 (2007).
45. Williams, A.B. et al. Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. *Blood* **120**, 3069-79 (2012).
46. Nielsen, S.F., Nordestgaard, B.G. & Bojesen, S.E. Statin use and reduced cancer-related mortality. *N Engl J Med* **367**, 1792-802 (2012).
47. Whyte, D.B. et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. *J Biol Chem* **272**, 14459-64 (1997).
48. Rowell, C.A., Kowalczyk, J.J., Lewis, M.D. & Garcia, A.M. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. *J Biol Chem* **272**, 14093-7 (1997).
49. Berndt, N., Hamilton, A.D. & Sebti, S.M. Targeting protein prenylation for cancer therapy. *Nat Rev Cancer* **11**, 775-91 (2011).
50. Lobell, R.B. et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. *Cancer Res* **61**, 8758-68 (2001).

Supplemental References

1. Krivtsov, A.V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. *Nature* **442**, 818-22 (2006).
2. Moore, M.A., Dorn, D.C., Schuringa, J.J., Chung, K.Y. & Morrone, G. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. *Exp Hematol* **35**, 105-16 (2007).

3. van Os, R.P., de Haan, G., Dethmers-Ausema, B. . In Vitro Assays for Cobblestone Area-Forming Cells, LTC-IC, and CFU-C. in *Methods In Molecular Biology*, Vol. 430 (ed. Bunting, K.D.) 143-157 (Humana Press, Totowa, 2008).